http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0179285-A9
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_be48fe5f903edced658b220be4e6e72f |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70596 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-705 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 |
| filingDate | 2001-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_42c86bd9708491067ddb11d1e150ffd8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_157c40baed26a2128531c5ad3c6483a2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_43e434bd7bc7d565cdc83516a975a074 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_551ea02ef4090297e60ad1e74aee20a7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6cb211cdebae728f417d489b1c9da2dd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da96ac73ce2bff24273e9df08aa6d060 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_11f8c5376b44f272a3cf4c30bfe12f88 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_afbcfa5d18fa1894f55c92528cc7774a |
| publicationDate | 2003-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-0179285-A9 |
| titleOfInvention | Methods and compositions for the treatment of fibrotic conditions and impaired lung function and to enhance lymphocyte production |
| abstract | The present invention provides methods and compositions to treat fibrotic conditions, to increase lymphocyte production in vivo, and to improve and/or normalize lung function, pulmonary compliance, blood oxygenation, and blood pH to inhibit inflammatory processes to stimulate or inhibit pro-inflammatory and immune cells, and to inhibit migration of vascular endothelial cells. The invention contemplates the administration of human uteroglobin, native or recombinant, as a means of achieving these ends. Specifically, it has been found that uteroglobin inhibits cell adhesion to fibronectin, increases lymphocyte production in vivo, and improves and/or normalizes lung function, pulmonary compliance, blood oxygenation, and blood pH, and inhibits inflammatory process. In addition it has been found that uteroglobin can stimulate or inhibit pro-inflammatory and immune cells and inhibitor migration of vascular endothelial cells. |
| priorityDate | 2000-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 337.